AP
REGN icon

Antipodes Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Antipodes Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97
Closed -$74.9K – 149
2026
Q1 		$74.9K Hold
97
– – ﹤0.01% 100
2025
Q4 		$74.9K Buy
+97
New +$65.9K ﹤0.01% 96

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Antipodes Partners's REGN Position: Q2 2026 in Review

Antipodes Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 97 shares — an estimated $74.9K sold.

Antipodes Partners first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $74.9K in Q1 2026. 789 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Antipodes Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 97 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $74.9K.
  • Antipodes Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Antipodes Partners's Regeneron Pharmaceuticals position peaked at $74.9K in Q1 2026.
  • 789 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.